Sign in

Cameron Bozdog

Research Analyst at Bank of America Corp. /de/

Cameron Bozdog is an Equity Research Associate at Bank of America, specializing in equity research analysis across key industry sectors. He began his tenure at Bank of America in 2025, focusing on delivering detailed investment insights and supporting senior analysts in covering notable publicly traded companies. Bozdog’s career includes substantial experience in equity research, and although metrics specific to his performance and company coverage are not publicly listed, his current responsibilities include rigorous financial modeling and market analysis. He maintains professional credentials consistent with research associate roles at major financial institutions.

Cameron Bozdog's questions to Acumen Pharmaceuticals (ABOS) leadership

Question · Q3 2024

Cameron Bozdog, on for Jason Zemansky at Bank of America, asked for key leading indicators, such as enrollment pace, that could give investors confidence that the Phase II ALTITUDE-AD trial remains on track.

Answer

CEO Daniel O'Connell highlighted that the enrollment rate for the ALTITUDE-AD study has been a significant positive indicator, progressing much faster than initially anticipated. He attributed the rapid enrollment to the compelling profile of sabirnetug, including its proof-of-mechanism from Phase I and a safety profile that has generated enthusiasm among investigators and trial participants.

Ask follow-up questions

Fintool

Fintool can predict Acumen Pharmaceuticals logo ABOS's earnings beat/miss a week before the call

Cameron Bozdog's questions to CYTOKINETICS (CYTK) leadership

Question · Q3 2024

Cameron Bozdog of Bank of America questioned which factors, such as safety or efficacy, would be most critical in justifying a potential pricing premium for aficamten.

Answer

Robert I. Blum, President and CEO, clarified that the company anticipates pricing in the 'same ZIP code' as the competitor, not at a premium. Andrew Callos, EVP and CCO, added that the focus is on achieving access parity. Blum emphasized that market research indicates risk mitigation and a favorable safety profile are key to driving broader physician adoption.

Ask follow-up questions

Fintool

Fintool can predict CYTOKINETICS logo CYTK's earnings beat/miss a week before the call